

Stress Ulcer Prophylaxis in the Intensive Care Unit

Information for nursing staff

Your department enrols patients in the SUP-ICU trial

The SUP-ICU trial compares pantoprazole and placebo as stress ulcer prophylaxis for critically ill patients

The SUP-ICU trial enrols 3350 patients at intensive care units in Europe

The SUP-ICU trial is supported by governmental funding and is approved by all relevant authorities

Queries? Please contact:

contact@sup-icu.com

Mette Krag, coordinating investigator Mette.krag.01@regionh.dk Phone: +45 3545 7450

Morten Hylander Møller, sponsor Mortenhylander@gmail.com Phone: +45 3545 8685



The nurse's role in SUP-ICU

New patients in the department

A large number of adults acutely admitted to the ICU will be eligible for inclusion in the SUP-ICU trial. Please remind clinicians that they have to consider enrolment of the patient in the trial before prescribing stress ulcer prophylaxis (e.g. pantoprazole, omeprazole, ranitidine and cimetidine) for the patient.

Daily administration of trial medication

During ICU stay the trial medication has to be given once daily (maximum 90 days).

Daily allocation of trial medication

The clinician randomising the patient has received the first vial identifier number when randomising the patient. Go directly to 10 if it is the first dose.

- 1. Visit www.sup-icu.com
- 2. Click 'Trial medication'
- 3. Login with the shared login of your department
- 4. Mark the patient at the list
- 5. Write your name in the box
- 6. Click 'Dispense vial to participant'
- 7. Confirm
- 8. The vial identifier number will appear
- 9. You have the option to print the number
- 10. Add 10 ml sodium chloride 0.9% to the vial, agitate gently and administer the medication to the patient as usual.

A detailed manual with pictures is available at www.sup-icu.com

Please ask the clinician to prescribe the trial medication in the medication chart/ICU chart as 'SUP-ICU trial medication intravenously once daily' (if possible).

Aside from trial medication patient management will be otherwise unaffected.

Information about SUP-ICU

Background

Critically ill patients are at risk of developing gastrointestinal bleeding and stress ulcer prophylaxis (SUP) is recommended. However, the evidence supporting prevention of stress related gastrointestinal bleeding is lacking. Furthermore, research has indicated that SUP may increase the risk of pneumonia, clostridium difficile infection and cardiovascular complications.

The aim of the SUP-ICU trial is to assess benefits and harms of SUP with pantoprazole for adult critically ill patients in the ICU and hereby improve the evidence base for the use of SUP in the ICU.

Methods

A total of 3350 patients in ICUs in Europe will be randomised to receive

either

 Pantoprazole 40 mg (added 10 ml of sodium chloride 0.9%)

or

 Placebo (sterile air filled vial added 10 ml sodium chloride 0.9%)

Aside from trial medication patient management will be otherwise unaffected

Results

At the end of the trial we will assess mortality and the incidence of gastrointestinal bleeding, pneumonia, clostridium difficile infection and cardiovascular complications in the two groups.

Funding

The trial has a budget at 17 million Danish kroner (2.3 mil Euro) and is funded by governmental funding (Innovation Fund Denmark)

The full protocol is available at www.sup-icu.com

Instructions

Trial instructions and other relevant documents are available at www.sup-icu.com (Trial documents)

Queries?

If you have any queries please do not hesitate to contact coordinating investigator Mette Krag. See contact information at the back of this leaflet.

Do you need help?
Call the SUP-ICU Hotline
+45 3545 7450
Available 24/7
OR
contact@sup-icu.com